Home Ingredients Lactobacillus paracasei (Multi-Strain Specialist)
Immune SupportRespiratory HealthGut Health

Lactobacillus paracasei (Multi-Strain Specialist)

Lacticaseibacillus paracasei (formerly Lactobacillus paracasei) — multiple strains
Evidence Level
Moderate
3 Clinical Trials
6 Documented Benefits
3/5 Evidence Score

A probiotic species (recently reclassified taxonomically as Lacticaseibacillus paracasei) with multiple strain-specific clinical applications — strain selection is essential because different strains have distinct evidence bases. Key strains: L. casei 431® (Chr. Hansen) for respiratory symptoms; KW3110 (Kirin) for pollen allergy; NCC2461 (Nestlé) for allergic rhinitis; GM-080 (Genmont) for pediatric allergic rhinitis; IJH-SONE68 (plant-derived) for chronic allergy. A large RCT of L. casei 431® reduced upper respiratory symptom duration but had no effect on influenza vaccine antibody titers. Generic 'L. paracasei' supplements should not be assumed equivalent to evidence-based strains.

Studied Dose L. casei 431: ≥1×10^9 CFU/day. KW3110 (pollen allergy): 4×10^10 CFU/day. GM-080 (pediatric AR): 2×10^9 CFU/day.
Active Compound Lacticaseibacillus paracasei (formerly Lactobacillus paracasei) — strains: L. casei 431 (Chr. Hansen), KW3110 (Kirin), NCC2461 (Nestlé), GM-080 (Genmont), IJH-SONE68, LT12, Shirota-type.

Benefits

Upper respiratory symptom duration

A randomized double-blind placebo-controlled trial in healthy adults gave >=1x10^9 CFU L. casei 431® daily with influenza vaccination and reduced the duration of upper respiratory symptoms. Honest framing: NO effect on antibody response — the respiratory symptom benefit does not translate to improved vaccine antibody titers. Different mechanism: mucosal immunity vs systemic antibody response.

Supported by Trial 1

Pollen allergy (KW3110, Kirin)

L. paracasei KW3110, given as 4x10^10 CFU/day yogurt to pollen allergy patients, repressed Th2 cell generation and eosinophil activation. Small sample size for this indication; suggests a Th1/Th2 immune balance shift toward Th1 dominance.

Supported by Trial 1

Pediatric allergic rhinitis (GM-080)

In pediatric perennial allergic rhinitis patients, 2x10^9 CFU/day GM-080 produced significant improvement in sneezing and Investigator Global Assessment vs placebo. Pediatric-specific evidence for the GM-080 strain.

Supported by Trial 2

Allergic rhinitis (NCC2461, Nestlé)

NCC2461 (Nestlé) — initial pilot proof of efficacy in allergic rhinitis volunteers, with a crossover trial extending the evidence. Distinct strain-specific evidence base — should not be assumed equivalent to other L. paracasei strains.

Supported by Trial 1, Trial 2

Chronic allergy (IJH-SONE68 plant-derived)

In chronic allergy subjects, IJH-SONE68 produced significant self-assessed allergic status and inflammation marker improvements. Plant-derived (pineapple juice broth fermentation) — important option for vegan or dairy-allergic populations.

Supported by Trial 3

meta-analysis of probiotics for AR (30 RCTs)

A meta-analysis of probiotics for allergic rhinitis improved Rhinitis QoL and Total Symptom scores, but not immunological parameters (eosinophil count, IgE titers unchanged). Honest framing: probiotic AR benefits are symptomatic, not immunological — clinical relevance present but mechanistic understanding incomplete.

Supported by Trial 1, Trial 2

Mechanism of action

1

Th1 induction and Th2 repression

Distinguishing immunomodulation profile — shifts the balance toward Th1 (which is suppressive of allergic Th2 responses). Mechanistic basis for the allergy-specific applications across strains.

2

TLR2 and dendritic cell activation

L. paracasei strains activate TLR2 receptors on dendritic cells, modulating downstream T cell polarization. Foundational innate immune pathway.

3

Exopolysaccharide (EPS) bioactivity (IJH-SONE68)

IJH-SONE68 specifically produces an exopolysaccharide with documented bioactivity. Strain-specific structural feature that may underlie the chronic-allergy benefits beyond standard L. paracasei pathways.

4

Strain-specific bioactive profiles

L. casei 431® vs KW3110 vs NCC2461 vs GM-080 vs IJH-SONE68 each have distinct bioactive profiles. Strain-level chemistry differs; clinical evidence cannot be transferred between strains.

5

Eosinophil activation suppression

KW3110 — repressed eosinophil activation in pollen allergy patients. Mechanistic finding consistent with the Th1 shift.

6

Mucosal vs systemic immunity (vaccine response evidence)

Respiratory symptom benefit occurs without vaccine antibody response improvement — suggesting the strain operates at the mucosal level (reducing local respiratory pathology) rather than via systemic antibody enhancement. Different mechanism than most vaccine-adjuvant approaches.

Clinical trials

1
L. casei 431® Influenza Vaccine 1,104-pt Clinical Trial (pivotal)

Clinical evidence on Lactobacillus paracasei (Multi-Strain Specialist) for the indications and outcomes described.

healthy adults

Trilling B et al. 2015 (Am J Clin Nutr 102:330-340). Randomized double-blind placebo-controlled trial in 1,104 healthy adults aged 18-60 at 2 centers (Germany + Denmark). ≥1×10⁹ CFU L. casei 431® for 42 days with day-21 influenza vaccination. Reduced duration of upper respiratory symptoms; NO effect on antibody response components. Important honest finding: respiratory symptom benefit does not translate to improved vaccine antibody titers.

2
GM-080 — Pediatric Allergic Rhinitis 122-Patient 3-Month Clinical Trial

122 pediatric perennial allergic rhinitis patients on 2×10⁹ CFU/day GM-080 for 3 months.

Clinical population described in trial publication.

122 pediatric perennial allergic rhinitis patients on 2×10⁹ CFU/day GM-080 for 3 months. Significant improvement in sneezing and Investigator Global Assessment vs placebo.

3
PMC8623948 — IJH-SONE68 Chronic Allergy 60-Subject 12-Week Clinical Trial

60 chronic allergy subjects on IJH-SONE68 for 12 weeks.

Clinical population described in trial publication.

60 chronic allergy subjects on IJH-SONE68 for 12 weeks. Significant self-assessed allergic status and inflammation marker improvements. Plant-derived (pineapple juice broth fermentation) — option for vegan or dairy-allergic populations.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; food-grade probiotic origin.
Mild GI upset, bloating (rare; transient).
Pregnancy/lactation: food-grade origin supports general safety; specific data limited.
Long-term safety: multiple multi-month trials supportive.
Allergic reactions in milk-derived ingredient sensitivities (rare; plant-derived IJH-SONE68 alternative).
Industry-sponsorship variable across strains — important context.
Strain identity verification important — generic 'L. paracasei' not equivalent.

Important Drug interactions

Antibiotics: take 2-3 hours apart from probiotic dose.
Most medications: well-tolerated combination profile.
Antihistamines: theoretical complementary effects in allergic rhinitis.
Vaccines: NO antibody response enhancement (Trilling 2015 negative finding) but possible respiratory symptom reduction.
Immunosuppressants: caution (applies to all probiotics).
Other probiotics: compatible.

Featured in these supplement guides

Allergies→Eczema & Skin Inflammation→

More Immune Support Ingredients

Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble essential nutrient that humans cannot synth…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…
Immune Support
Vitamin A
Vitamin A is a fat-soluble nutrient essential for vision, immune defense, reproduction, an…
Immune Support
EpiCor® (Postbiotic Yeast Fermentate — Cargill)
EpiCor is a postbiotic ingredient from Cargill, derived from the fermentation of Saccharom…

Explore Other Ingredients

Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Immune Support
Reishi Mushroom
Reishi (Ganoderma lucidum) is a revered medicinal mushroom traditionally called the mushro…

Frequently asked questions about Lactobacillus paracasei (Multi-Strain Specialist)

What is Lactobacillus paracasei used for?

L. paracasei is studied for immune support, easing allergic rhinitis (hay fever) symptoms, skin health, and general gut balance. Certain strains have specific research for seasonal allergy comfort.

Does L. paracasei help with allergies?

Some strains of L. paracasei have research suggesting they may ease allergic rhinitis symptoms by modulating the immune response. The benefit is strain-specific, so choose a product studied for allergy support.

How much L. paracasei should I take?

Common doses provide about 1 to 10 billion CFU per day, taken once daily. For seasonal allergy support, starting before allergy season is a common approach.

Is L. paracasei safe?

It is generally very safe and well tolerated. As with all live probiotics, severely immunocompromised or critically ill people should check with a doctor first.

What is Lactobacillus paracasei?

A probiotic species (recently reclassified taxonomically as Lacticaseibacillus paracasei) with multiple strain-specific clinical applications — strain selection is essential because different strains have distinct evidence bases. Key strains: L. casei 431® (Chr.

What is the recommended dosage of Lactobacillus paracasei?

The clinically studied dose is L. casei 431: ≥1×10^9 CFU/day. KW3110 (pollen allergy): 4×10^10 CFU/day. GM-080 (pediatric AR): 2×10^9 CFU/day. Always follow the product label and check with a healthcare provider for personal advice.

Is Lactobacillus paracasei safe, and does it have side effects?

For most healthy adults, Lactobacillus paracasei is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; food-grade probiotic origin. Mild GI upset, bloating (rare; transient). It may also interact with some medications. Lactobacillus paracasei is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Lactobacillus paracasei interact with any medications?

Possible interactions include: Antibiotics: take 2-3 hours apart from probiotic dose. Most medications: well-tolerated combination profile. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Lactobacillus paracasei?

NutraSmarts rates the evidence for Lactobacillus paracasei as Moderate (3 out of 5). It is backed by 3 clinical trials and 1 cited reference summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Lin EK, Chang WW, Jhong JH, et al. Lacticaseibacillus paracasei GM-080 Ameliorates Allergic Airway Inflammation in Children with Allergic Rhinitis: From an Animal Model to a Double-Blind, Randomized, Placebo-Controlled Trial. Cells. 2023;12(5)..PubMedUsed to support: Randomized trial of Lactobacillus paracasei (GM-080) for allergic rhinitis in children.